Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced

AIMS: Baseline body mass index (BMI) and weight loss promoted by sodium–glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR‐Reduced population treated with empagliflozin versus placebo the relationsh...

Descripción completa

Detalles Bibliográficos
Autores principales: Anker, Stefan D., Khan, Muhammad Shahzeb, Butler, Javed, Ofstad, Anne Pernille, Peil, Barbara, Pfarr, Egon, Doehner, Wolfram, Sattar, Naveed, Coats, Andrew J. S., Filippatos, Gerasimos, Ferreira, João Pedro, Zannad, Faiez, Pocock, Stuart, Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Medical Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098519/
https://www.ncbi.nlm.nih.gov/pubmed/36325584
http://dx.doi.org/10.1002/ejhf.2728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098519/
https://www.ncbi.nlm.nih.gov/pubmed/36325584
http://dx.doi.org/10.1002/ejhf.2728

Ejemplares similares